AU2017278114B2 - Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide - Google Patents

Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide Download PDF

Info

Publication number
AU2017278114B2
AU2017278114B2 AU2017278114A AU2017278114A AU2017278114B2 AU 2017278114 B2 AU2017278114 B2 AU 2017278114B2 AU 2017278114 A AU2017278114 A AU 2017278114A AU 2017278114 A AU2017278114 A AU 2017278114A AU 2017278114 B2 AU2017278114 B2 AU 2017278114B2
Authority
AU
Australia
Prior art keywords
compound
administered
subject
days
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017278114A
Other languages
English (en)
Other versions
AU2017278114A1 (en
Inventor
Soraya Carrancio
Paul Hollenbach
Antonia Lopez-Girona
Gang Lu
Kyle Macbeth
Michael POURDEHNAD
Irit Rappley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AU2017278114A1 publication Critical patent/AU2017278114A1/en
Application granted granted Critical
Publication of AU2017278114B2 publication Critical patent/AU2017278114B2/en
Priority to AU2023202159A priority Critical patent/AU2023202159A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017278114A 2016-06-06 2017-06-05 Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide Active AU2017278114B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023202159A AU2023202159A1 (en) 2016-06-06 2023-04-06 Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346344P 2016-06-06 2016-06-06
US62/346,344 2016-06-06
PCT/US2017/035892 WO2017214014A1 (en) 2016-06-06 2017-06-05 Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023202159A Division AU2023202159A1 (en) 2016-06-06 2023-04-06 Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Publications (2)

Publication Number Publication Date
AU2017278114A1 AU2017278114A1 (en) 2018-11-29
AU2017278114B2 true AU2017278114B2 (en) 2023-01-12

Family

ID=60482040

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017278114A Active AU2017278114B2 (en) 2016-06-06 2017-06-05 Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
AU2023202159A Abandoned AU2023202159A1 (en) 2016-06-06 2023-04-06 Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023202159A Abandoned AU2023202159A1 (en) 2016-06-06 2023-04-06 Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Country Status (15)

Country Link
US (4) US10245258B2 (cg-RX-API-DMAC7.html)
EP (1) EP3463358A4 (cg-RX-API-DMAC7.html)
JP (1) JP7163281B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190015300A (cg-RX-API-DMAC7.html)
CN (2) CN109414436A (cg-RX-API-DMAC7.html)
AU (2) AU2017278114B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018075206A2 (cg-RX-API-DMAC7.html)
CA (1) CA3026396A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018003499A1 (cg-RX-API-DMAC7.html)
EA (1) EA201892746A1 (cg-RX-API-DMAC7.html)
IL (1) IL262565B (cg-RX-API-DMAC7.html)
MX (1) MX388717B (cg-RX-API-DMAC7.html)
SG (1) SG11201809501PA (cg-RX-API-DMAC7.html)
WO (1) WO2017214014A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201807105B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
US10648983B2 (en) * 2016-01-08 2020-05-12 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
US11535603B1 (en) 2016-09-30 2022-12-27 Deuterx, Llc Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same
WO2018102725A1 (en) 2016-12-01 2018-06-07 Arvinas, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
EA202191833A1 (ru) * 2018-12-31 2021-10-11 Селджин Корпорейшн Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида
AU2020336309A1 (en) 2019-08-26 2022-03-17 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN115607552B (zh) 2019-10-21 2024-06-18 新基公司 取代的4-氨基异二氢吲哚-1,3-二酮化合物和第二种活性剂的组合用途
JP2022554346A (ja) * 2019-11-05 2022-12-28 セルジーン コーポレーション ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドとの併用療法
CN114761004A (zh) 2019-12-06 2022-07-15 细胞基因公司 用于制备2-(4-氯苯基)-n-((2-(2，6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2，2-二氟乙酰胺的方法
IL296557A (en) * 2020-03-16 2022-11-01 Celgene Corp Combined treatment for acute myeloid leukemia
TW202214236A (zh) * 2020-09-14 2022-04-16 美商亞文納營運公司 用於靶向降解雌激素受體之化合物之結晶及非晶形形式
KR102499522B1 (ko) 2020-09-23 2023-02-13 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 세레브론 단백질의 조절제로서의 치환된 n-(2-(2,6-디옥소피페리딘-3-일)-1,3-디옥소이소인돌린-5-일)아릴설폰아미드 유사체
KR20240066906A (ko) * 2022-11-08 2024-05-16 주식회사 온코드바이오 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220144A1 (en) * 2002-10-15 2004-11-04 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US20150157603A1 (en) * 2013-12-05 2015-06-11 Hoffmann-La Roche Inc. Novel combination treatment for acute myeloid leukemia (aml)
WO2016007848A1 (en) * 2014-07-11 2016-01-14 Celgene Corporation Antiproliferative compounds and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100391464C (zh) * 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20090175869A1 (en) * 2007-05-31 2009-07-09 Ascenta Therapeutics, Inc. Pulsatile Dosing of Gossypol for Treatment of Disease
DK2263677T3 (da) 2009-05-20 2011-06-06 Hybrigenics Sa Nye terapeutiske anvendelser af inecalcitol
AU2012318239B2 (en) * 2011-11-01 2015-07-09 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
MX382150B (es) 2016-01-08 2025-03-13 Celgene Corp Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.
MX385964B (es) 2016-01-08 2025-03-18 Celgene Corp Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos.
TWI782395B (zh) 2016-01-08 2022-11-01 美商西建公司 抗增生化合物，及其醫藥組合物及用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220144A1 (en) * 2002-10-15 2004-11-04 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US20150157603A1 (en) * 2013-12-05 2015-06-11 Hoffmann-La Roche Inc. Novel combination treatment for acute myeloid leukemia (aml)
WO2016007848A1 (en) * 2014-07-11 2016-01-14 Celgene Corporation Antiproliferative compounds and methods of use thereof

Also Published As

Publication number Publication date
BR112018075206A2 (pt) 2019-03-19
US11590117B2 (en) 2023-02-28
CL2018003499A1 (es) 2019-03-15
AU2017278114A1 (en) 2018-11-29
SG11201809501PA (en) 2018-12-28
ZA201807105B (en) 2020-01-29
US20210154182A1 (en) 2021-05-27
US20230158009A1 (en) 2023-05-25
US20190175573A1 (en) 2019-06-13
IL262565A (en) 2018-12-31
MX388717B (es) 2025-03-20
EP3463358A1 (en) 2019-04-10
WO2017214014A1 (en) 2017-12-14
CA3026396A1 (en) 2017-12-14
EA201892746A1 (ru) 2019-06-28
EP3463358A4 (en) 2020-07-22
MX2018015120A (es) 2019-04-15
US20170348298A1 (en) 2017-12-07
US10245258B2 (en) 2019-04-02
JP2019517587A (ja) 2019-06-24
KR20190015300A (ko) 2019-02-13
CN115282149A (zh) 2022-11-04
IL262565B (en) 2022-08-01
AU2023202159A1 (en) 2023-05-04
JP7163281B2 (ja) 2022-10-31
CN109414436A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
US20230158009A1 (en) Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
US11401257B2 (en) Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
EP3644999B1 (en) Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
EP3808346B1 (en) Antiproliferative compounds for use in the treatment of leukemia
US20230149379A1 (en) Combination therapy for acute myeloid leukemia
CN111542321A (zh) 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的同位素体
IL292582A (en) Use of biomarkers to predict clinical sensitivity to 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
NZ747409A (en) Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
HK40051637B (en) Antiproliferative compounds for use in the treatment of leukemia
HK40033324A (en) Isotopologues of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
HK40030243B (en) Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
HK40030243A (en) Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
HK40005153B (en) Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
HK40005153A (en) Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)